Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 7, 2012. The report announces the financial and operating results for the quarter ended June 30, 2012. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1), which is not part of the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2012.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. It serves solely as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., not Altimmune, Inc.
- Locate and review Exhibit 99.1 (Press Release dated August 7, 2012) for actual financial figures.
- Confirm the reporting period is the quarter ended June 30, 2012.
- Note that the information in this 8-K is not deemed "filed" for Section 18 liability purposes under the Exchange Act.